Keywords
Last Name

Ann Marie Egloff, PhD

TitleResearch Associate Professor
InstitutionBoston University Henry M. Goldman School of Dental Medicine
DepartmentMolecular & Cell Biology
Address72 E. Concord St.
Boston MA 02118
Phone(617) 414-1078
Other Positions
TitleResearch Associate Professor
InstitutionBoston University School of Medicine
DepartmentOtolaryngology-Head & Neck Surgery

 Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Wen Y, Li H, Zeng Y, Wen W, Pendleton KP, Lui VW, Egloff AM, Grandis JR. MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin. Oncotarget. 2016 Apr 26; 7(17):23300-11. PMID: 27004400.
    View in: PubMed
  2. Li H, Wheeler S, Park Y, Ju Z, Thomas SM, Fichera M, Egloff AM, Lui VW, Duvvuri U, Bauman JE, Mills GB, Grandis JR. Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts. Mol Cancer Res. 2016 Mar; 14(3):278-86. PMID: 26685214.
    View in: PubMed
  3. Van Allen EM, Lui VW, Egloff AM, Goetz EM, Li H, Johnson JT, Duvvuri U, Bauman JE, Stransky N, Zeng Y, Gilbert BR, Pendleton KP, Wang L, Chiosea S, Sougnez C, Wagle N, Zhang F, Du Y, Close D, Johnston PA, McKenna A, Carter SL, Golub TR, Getz G, Mills GB, Garraway LA, Grandis JR. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. JAMA Oncol. 2015 May; 1(2):238-44. PMID: 26181029.
    View in: PubMed
  4. Wheeler SE, Egloff AM, Wang L, James CD, Hammerman PS, Grandis JR. Challenges in EGFRvIII detection in head and neck squamous cell carcinoma. PLoS One. 2015; 10(2):e0117781. PMID: 25658924.
    View in: PubMed
  5. Fung C, Zhou P, Joyce S, Trent K, Yuan JM, Grandis JR, Weissfeld JL, Romkes M, Weeks DE, Egloff AM. Identification of epidermal growth factor receptor (EGFR) genetic variants that modify risk for head and neck squamous cell carcinoma. Cancer Lett. 2015 Feb 28; 357(2):549-56. PMID: 25511740.
    View in: PubMed
  6. Egloff AM, Lee JW, Langer CJ, Quon H, Vaezi A, Grandis JR, Seethala RR, Wang L, Shin DM, Argiris A, Yang D, Mehra R, Ridge JA, Patel UA, Burtness BA, Forastiere AA. Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303. Clin Cancer Res. 2014 Oct 1; 20(19):5041-51. PMID: 25107914.
    View in: PubMed
  7. Gross AM, Orosco RK, Shen JP, Egloff AM, Carter H, Hofree M, Choueiri M, Coffey CS, Lippman SM, Hayes DN, Cohen EE, Grandis JR, Nguyen QT, Ideker T. Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nat Genet. 2014 Sep; 46(9):939-43. PMID: 25086664.
    View in: PubMed
  8. Kagawa S, Natsuizaka M, Whelan KA, Facompre N, Naganuma S, Ohashi S, Kinugasa H, Egloff AM, Basu D, Gimotty PA, Klein-Szanto AJ, Bass AJ, Wong KK, Diehl JA, Rustgi AK, Nakagawa H. Cellular senescence checkpoint function determines differential Notch1-dependent oncogenic and tumor-suppressor activities. Oncogene. 2015 Apr 30; 34(18):2347-59. PMID: 24931169.
    View in: PubMed
  9. Choby GW, Albergotti WG, Byrd JK, Egloff AM, Johnson JT. Factors contributing to recurrence of oral cavity and laryngeal tumors and estimation of tumor age. Laryngoscope. 2014 Oct; 124(10):2297-304. PMID: 24913023.
    View in: PubMed
  10. Argiris A, Li S, Ghebremichael M, Egloff AM, Wang L, Forastiere AA, Burtness B, Mehra R. Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials. Ann Oncol. 2014 Jul; 25(7):1410-6. PMID: 24799460.
    View in: PubMed
  11. Li C, Egloff AM, Sen M, Grandis JR, Johnson DE. Caspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth. Mol Oncol. 2014 Oct; 8(7):1220-30. PMID: 24816188.
    View in: PubMed
  12. Hathaway B, Vaezi A, Egloff AM, Smith L, Wasserman-Wincko T, Johnson JT. Frailty measurements and dysphagia in the outpatient setting. Ann Otol Rhinol Laryngol. 2014 Sep; 123(9):629-35. PMID: 24707011.
    View in: PubMed
  13. Lei Y, Lui VW, Grandis JR, Egloff AM. Identification of mutations in the PYRIN-containing NLR genes (NLRP) in Head and Neck Squamous Cell Carcinoma. PLoS One. 2014; 9(1):e85619. PMID: 24465623.
    View in: PubMed
  14. Sok JC, Lee JA, Dasari S, Joyce S, Contrucci SC, Egloff AM, Trevelline BK, Joshi R, Kumari N, Grandis JR, Thomas SM. Collagen type XI a1 facilitates head and neck squamous cell cancer growth and invasion. Br J Cancer. 2013 Dec 10; 109(12):3049-56. PMID: 24231953.
    View in: PubMed
  15. Gillman GS, Egloff AM, Rivera-Serrano CM. Revision septoplasty: a prospective disease-specific outcome study. Laryngoscope. 2014 Jun; 124(6):1290-5. PMID: 23945947.
    View in: PubMed
  16. Leibowitz MS, Srivastava RM, Andrade Filho PA, Egloff AM, Wang L, Seethala RR, Ferrone S, Ferris RL. SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells. Clin Cancer Res. 2013 Feb 15; 19(4):798-808. PMID: 23363816.
    View in: PubMed
  17. Wan XC, Egloff AM, Johnson J. Histological assessment of cervical lymph node identifies patients with head and neck squamous cell carcinoma (HNSCC): who would benefit from chemoradiation after surgery? Laryngoscope. 2012 Dec; 122(12):2712-22. PMID: 23060119.
    View in: PubMed
  18. Egloff AM, Grandis JR. Molecular pathways: context-dependent approaches to Notch targeting as cancer therapy. Clin Cancer Res. 2012 Oct 1; 18(19):5188-95. PMID: 22773520.
    View in: PubMed
  19. Duvvuri U, Shiwarski DJ, Xiao D, Bertrand C, Huang X, Edinger RS, Rock JR, Harfe BD, Henson BJ, Kunzelmann K, Schreiber R, Seethala RS, Egloff AM, Chen X, Lui VW, Grandis JR, Gollin SM. TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression. Cancer Res. 2012 Jul 1; 72(13):3270-81. PMID: 22564524.
    View in: PubMed
  20. Dedhia K, Yellon RF, Branstetter BF, Egloff AM. Anatomic variants on computed tomography in congenital aural atresia. Otolaryngol Head Neck Surg. 2012 Aug; 147(2):323-8. PMID: 22467282.
    View in: PubMed
  21. Egloff AM, Liu X, Davis AL, Trevelline BK, Vuga M, Siegfried JM, Grandis JR. Elevated gastrin-releasing peptide receptor mRNA expression in buccal mucosa: association with head and neck squamous cell carcinoma. Head Neck. 2013 Feb; 35(2):270-9. PMID: 22431275.
    View in: PubMed
  22. Stapleton AL, Egloff AM, Yellon RF. Congenital cholesteatoma: predictors for residual disease and hearing outcomes. Arch Otolaryngol Head Neck Surg. 2012 Mar; 138(3):280-5. PMID: 22431873.
    View in: PubMed
  23. Wheeler S, Siwak DR, Chai R, LaValle C, Seethala RR, Wang L, Cieply K, Sherer C, Joy C, Mills GB, Argiris A, Siegfried JM, Grandis JR, Egloff AM. Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Clin Cancer Res. 2012 Apr 15; 18(8):2278-89. PMID: 22351687.
    View in: PubMed
  24. Egloff AM, Gaither Davis A, Shuai Y, Land S, Pilewski JM, Luketich JD, Landreneau R, Miller YE, Grandis JR, Siegfried JM. Gastrin-releasing peptide receptor expression in non-cancerous bronchial epithelia is associated with lung cancer: a case-control study. Respir Res. 2012; 13:9. PMID: 22296774.
    View in: PubMed
  25. Mburu YK, Egloff AM, Walker WH, Wang L, Seethala RR, van Waes C, Ferris RL. Chemokine receptor 7 (CCR7) gene expression is regulated by NF-?B and activator protein 1 (AP1) in metastatic squamous cell carcinoma of head and neck (SCCHN). J Biol Chem. 2012 Jan 27; 287(5):3581-90. PMID: 22158872.
    View in: PubMed
  26. Lee J, Phong B, Egloff AM, Kane LP. TIM polymorphisms--genetics and function. Genes Immun. 2011 Dec; 12(8):595-604. PMID: 22048452.
    View in: PubMed
  27. Argiris A, Feinstein TM, Wang L, Yang T, Agrawal S, Appleman LJ, Stoller RG, Grandis JR, Egloff AM. Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies. Invest New Drugs. 2012 Aug; 30(4):1575-84. PMID: 21881918.
    View in: PubMed
  28. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortés ML, Auclair D, Berger MF, Saksena G, Guiducci C, Onofrio RC, Parkin M, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escareño C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Winckler W, Ardlie K, Gabriel SB, Meyerson M, Lander ES, Getz G, Golub TR, Garraway LA, Grandis JR. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011 Aug 26; 333(6046):1157-60. PMID: 21798893.
    View in: PubMed
  29. Egloff AM, Grandis JR. Response to combined molecular targeting: defining the role of P-STAT3. Clin Cancer Res. 2011 Feb 1; 17(3):393-5. PMID: 21266530.
    View in: PubMed
  30. Pectasides E, Egloff AM, Sasaki C, Kountourakis P, Burtness B, Fountzilas G, Dafni U, Zaramboukas T, Rampias T, Rimm D, Grandis J, Psyrri A. Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis. Clin Cancer Res. 2010 Apr 15; 16(8):2427-34. PMID: 20371693.
    View in: PubMed
  31. Amin W, Kang HP, Egloff AM, Singh H, Trent K, Ridge-Hetrick J, Seethala RR, Grandis J, Parwani AV. An informatics supported web-based data annotation and query tool to expedite translational research for head and neck malignancies. BMC Cancer. 2009; 9:396. PMID: 19912644.
    View in: PubMed
  32. Egloff AM, Rothstein ME, Seethala R, Siegfried JM, Grandis JR, Stabile LP. Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma. Clin Cancer Res. 2009 Nov 1; 15(21):6529-40. PMID: 19825947.
    View in: PubMed
  33. Egloff AM, Grandis JR. Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors. J Oncol. 2009; 2009:896407. PMID: 19636423.
    View in: PubMed
  34. Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, Suzuki S, Quesnelle KM, Morgan S, Ferris RL, Grandis JR, Siegfried JM. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res. 2009 Jun 1; 15(11):3740-50. PMID: 19470725.
    View in: PubMed
  35. Egloff A, Feinstein TM, Joyce SC, Kelly LA, Panelli MC, Yang T, Siegfried JM, Grandis JR, Argiris A. Blood biomarker modulation with dasatinib (D) and cetuximab (C) in patients (pts) with advanced solid malignancies. J Clin Oncol. 2009 May 20; 27(15_suppl):6034. PMID: 27961909.
    View in: PubMed
  36. Lai SY, Koppikar P, Thomas SM, Childs EE, Egloff AM, Seethala RR, Branstetter BF, Gooding WE, Muthukrishnan A, Mountz JM, Lui VW, Shin DM, Agarwala SS, Johnson R, Couture LA, Myers EN, Johnson JT, Mills G, Argiris A, Grandis JR. Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms. J Clin Oncol. 2009 Mar 10; 27(8):1235-42. PMID: 19204206.
    View in: PubMed
  37. Koppikar P, Choi SH, Egloff AM, Cai Q, Suzuki S, Freilino M, Nozawa H, Thomas SM, Gooding WE, Siegfried JM, Grandis JR. Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res. 2008 Jul 1; 14(13):4284-91. PMID: 18594011.
    View in: PubMed
  38. Egloff AM, Grandis JR. Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer. Semin Oncol. 2008 Jun; 35(3):286-97. PMID: 18544443.
    View in: PubMed
  39. Chiosea SI, Barnes EL, Lai SY, Egloff AM, Sargent RL, Hunt JL, Seethala RR. Mucoepidermoid carcinoma of upper aerodigestive tract: clinicopathologic study of 78 cases with immunohistochemical analysis of Dicer expression. Virchows Arch. 2008 Jun; 452(6):629-35. PMID: 18239938.
    View in: PubMed
  40. Egloff AM, Grandis J. Epidermal growth factor receptor-targeted molecular therapeutics for head and neck squamous cell carcinoma. Expert Opin Ther Targets. 2006 Oct; 10(5):639-47. PMID: 16981821.
    View in: PubMed
  41. Egloff AM, Vella LA, Finn OJ. Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Res. 2006 Jan 1; 66(1):6-9. PMID: 16397206.
    View in: PubMed
  42. Egloff AM, Weissfeld J, Land SR, Finn OJ. Evaluation of anticyclin B1 serum antibody as a diagnostic and prognostic biomarker for lung cancer. Ann N Y Acad Sci. 2005 Dec; 1062:29-40. PMID: 16461786.
    View in: PubMed
  43. Egloff AM, Desiderio S. Identification of phosphorylation sites for Bruton's tyrosine kinase within the transcriptional regulator BAP/TFII-I. J Biol Chem. 2001 Jul 27; 276(30):27806-15. PMID: 11373296.
    View in: PubMed
  44. Zhu G, Wu LH, Mauzy C, Egloff AM, Mirzadegan T, Chung FZ. Replacement of lysine-181 by aspartic acid in the third transmembrane region of endothelin type B receptor reduces its affinity to endothelin peptides and sarafotoxin 6c without affecting G protein coupling. J Cell Biochem. 1992 Oct; 50(2):159-64. PMID: 1429881.
    View in: PubMed
Ann's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Similar BU People
_
Same Department